secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2022-12-20T23:59:59+00:00
Accession:  0001193125-22-309133
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical submits FDA PMA application for RECELL System to treat stable vitiligo
--------------------------------------------------------------------------------

- PMA submitted to FDA to expand RECELL indication to stable vitiligo; received Breakthrough Device designation.
- Pivotal trial met primary endpoint of super-superiority (p<0.025) on repigmentation success rates.
- Standard FDA review timeline for PMA is 180 days; full launch anticipated January 2025 if approved.
- Vitiligo affects up to 6.5M Americans (~1.3M stable); limited treatment options exist.
- This PMA follows original RECELL approval for burns in September 2018.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312522309133/0001193125-22-309133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312522309133/d434009d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-309133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer